Samsung Bioepis has surpassed its total annual revenue from last year within the first three quarters of 2023. The company’s annual revenue is projected to exceed 1.4 trillion KRW (approx. $1…

Boryung is getting closer to achieving 1 trillion KRW ($740 million) in annual sales for the first time, supported by strong third-quarter results. Its growth has been boosted by its co-promotion and…

Yuhan Corporation’s third-quarter operating profit has skyrocketed, primarily due to license revenue from its out-licensed non-small cell lung cancer drug Leclaza. On the 28th, Yuhan reported that…

Following Samsung Biologics’ announcement of its third-quarter results, several securities firms have raised their target stock price for the company. This is largely due to the rapid ramp-up of…

SK bioscience announced that its quadrivalent cell-culture influenza vaccine, SkyCellflu Quadrivalent Pre-filled Syringe(SkyCellflu), has obtained final market authorization from the Indonesian…

Samsung Biologics has made headlines again. On the 22nd, the company announced that it had signed a massive Contract Manufacturing Organization (CMO) deal worth 1.7028 trillion KRW ($1.24 billion)…

It's been two and a half years since OCI became the largest shareholder of Bukwang Pharmaceutical, yet instead of generating synergy, Bukwang's financial performance has continued to falter. On the…

Contrast-enhanced mammography (CEM) is gaining attention as a crucial method in the fight against breast cancer, the most common cancer among Korean women. At a press conference hosted by GE…

DongKook Pharmaceutical strengthens its cosmetics business by acquiring ReBom Cosmetics. On the 16th, DongKook Pharmaceutical announced that it had signed a contract to acquire ReBom Cosmetics, a…

STGen Bio announced on the 14th that its Songdo Bio Plant has received current Good Manufacturing Practice (cGMP) approval from the U.S. Food and Drug Administration (FDA). The approval covers the…